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Abstract
To overcome the problem of overlooking colorectal tumors, a new and highly sensitive modality of colonoscopy is needed. Moreover, it is also important to establish a new modality to evaluate viable tumor volume in primary lesions of colorectal cancer (CRC) during chemotherapy. Therefore, we carried out molecular imaging of colorectal tumors targeting epidermal growth factor receptor (EGFR), which is highly expressed on tumor cells, for evaluating chemotherapeutic efficacy and for endoscopic detection of colorectal adenomas. We first attempted to image five CRC cell lines with various levels of EGFR expression using an Alexa Fluor-labeled anti-EGFR monoclonal antibody (AF-EGFR-Ab). A strong fluorescence signal was observed in the cells depending on the level of EGFR expression. When nude mice xenografted with LIM1215 CRC cells, which highly express EGFR, were i.v. injected with AF-EGFR-Ab, a strong fluorescence signal appeared in the tumor with a high signal to noise ratio, peaking at 48 hours after injection and then gradually decreasing, as shown using an IVIS Spectrum system. When the xenografted mice were treated with 5-fluorouracil, fluorescence intensity in the tumor decreased in proportion to the viable tumor cell volume. Moreover, when the colorectum of azoxymethane-treated rats was observed using a thin fluorescent endoscope with AF-EGFR-Ab, all 10 small colorectal adenomas (≤3 mm) were detected with a clear fluorescence signal. These preliminary results of animal experiments suggest that EGFR-targeted fluorescent molecular imaging may be useful for quantitatively evaluating cell viability in CRC during chemotherapy, and also for detecting small adenomas using a fluorescent endoscope.
| INTRODUC TI ON
Colorectal cancer is one of the leading causes of cancer-related death worldwide.
1 It is well known that CRC develops mainly from colorectal adenoma, a precancerous lesion in the colorectum. [2] [3] [4] Therefore, it is important to remove colorectal adenoma before it develops into cancer. However, it has been reported that 15%-32% of colorectal tumors are overlooked during colonoscopy. 5 Thus, improved endoscopy capable of more sensitive detection of colorectal tumors is needed.
In addition, evaluation of tumor size in response to chemotherapy is critical in the treatment of metastatic CRC. 6 Currently, response to treatment in CRC is evaluated by CT using RECIST criteria. 7 Only measurable metastatic lesions in patients with CRC are evaluated by measuring tumor size in CT images based on RECIST criteria.
However, it is difficult to evaluate viable tumor cells accurately because the central part of the tumor often undergoes necrosis as a result of chemotherapy or other factors. [8] [9] [10] Moreover, there is no method to objectively evaluate tumor volume of primary lesions in the colorectum during chemotherapy. A new imaging modality to accurately assess viable tumor volume of CRC is therefore needed.
Molecular imaging is a good candidate modality for the detection of small colorectal tumors with high sensitivity and accurately evaluates the viability of colorectal tumors. Furthermore, molecular imaging also makes it possible to distinguish malignant and benign lesions, and to accurately assess tumor margin. 11 However, a practical molecular imaging technology that improves the detection of small tumors and enables evaluation of viable tumor cell volume before and after chemotherapy has yet to be established.
12
Epidermal growth factor receptor is a transmembrane-type tyrosine kinase. EGFR is commonly expressed on the cell surface of CRC and precancerous adenomas, and is strongly associated with proliferation, invasion, metastasis, poor prognosis, and early recurrence of CRC. [13] [14] [15] [16] EGFR is expressed on the cell membrane surface, and the expression level is highest in cancer, moderate in adenoma, and very low in normal epithelia. Thus, EGFR is suitable as a target for molecular imaging of colorectal tumors.
Although several studies on molecular imaging of CRC targeting EGFR have been published, [17] [18] [19] [20] [21] no studies on molecular imaging for precancerous adenomas targeting EGFR have been reported. In addition, no studies have investigated the utility of EGFR-targeted molecular imaging of viable tumor cells in CRC before and after treatment with anticancer agents. In the present study, we first examined whether fluorescence-labeled anti-EGFR antibody is able to visualize CRC in vitro and in vivo depending on EGFR expression level. We also investigated the utility of EGFR-targeted molecular imaging for the evaluation of viable cell volume before and after chemotherapy in animal models of CRC. We then carried out molecular imaging of small colorectal adenomas in a rat model using a fluorescence-labeled anti-EGFR antibody.
| MATERIAL S AND ME THODS

| Cell lines
The CRC cell lines DLD- 
| Quantification of cell surface EGFR by flow cytometry
Quantitative flow cytometric analysis of EGFR on the cell surface was carried out using mouse antihuman EGFR monoclonal antibody (sc-120; Santa Cruz Biotechnology, Dallas, TX, USA) and Dako QIFIKIT (Dako, Glostrup, Denmark), as described previously. 22 In brief, cells were incubated with a mouse antihuman The cells were observed by confocal laser microscopy (Nikon A1;
| In vitro cell imaging and fluorescence intensity
Nikon, Tokyo, Japan) and bench top fluorescence microscopy (BIOREVO BZ9000; Keyence, Osaka, Japan). Images were captured using the Nikon A1, and signal intensity was calculated using the intrinsic software equipped with BIOREVO in each cell. in the tumor and in the background skin of the opposite side of each mouse, and the fluorescence intensities were calculated using software as described previously. 23 All animal experiments were carried out according to the Guidelines for Animal Experiments at Tokushima University.
| In vivo molecular imaging of xenograft tumors in mice
| Treatment with fluorouracil for xenograft tumors in nude mice
Sixteen nude mice xenografted with LIM1215 cells were randomly Fluorescence intensity of each tumor was calculated as described above.
| Veterinary endoscope for AOM-treated rats
Azoxymethane (AOM; Sigma-Aldrich Co., St Louis, MO, USA) was given to 10 5-week-old male F344 rats (Charles River Laboratories Japan, Inc., Yokohama, Japan) s.c. at a dose of 15 mg/kg once a week for 3 weeks according to the schedule described in Figure At 26 weeks, rats were fasted for 24 hours and given an enema with 2 mL PBS twice prior to colonoscopy for removal of feces.
During the procedure, rats were anesthetized with 2% isoflurane.
A thin endoscope with a diameter of 2.7 mm (70 mm length, AE-E27110; AVS Co. Ltd) was introduced through the anus and inserted into the splenic flexure with gentle insufflation using a specially designed cannula (AE-E27110-CAN-S; AVS Co. Ltd) attached to an air-pumping unit. The scope was then slowly withdrawn and the colorectal mucosa was carefully observed under white light. A 3-mL enema with AF488-EGFR-Ab (20 μg/mL), which was sufficient to immerse the distal side of the colorectum, was given after pretreatment with or without non-labeled mouse anti-human EGFR monoclonal antibody (200 μg/mL, sc-120; Santa Cruz Biotechnology).
After 3 minutes, 2 mL PBS was given as an enema twice for washing, and fluorescence observation was carried out. All images were captured in a dark room. Both white light and fluorescence images were recorded on a hard disk video recorder. S/N ratio was calculated as described previously. 
| Immunohistochemistry
Immunohistochemical staining for CEA was carried out using the catalyzed signal amplification (CSA) system, as previously described. 26 A rabbit antihuman CEA monoclonal antibody (ab133633;
Abcam, Cambridge, UK) was used as the primary antibody. For EGFR staining, the labeled streptavidin-biotin-peroxidase (LSAB) method was carried out as previously described. 27 A rabbit antihuman EGFR monoclonal antibody (ab52894; Abcam, Cambridge, UK) was used as the primary antibody.
| Quantification of CEA-positivity rate in tumor tissues
Carcinoembryonic antigen expression areas were quantified using WinROOF Version 6.3 software (Mitani Corp., Tokyo, Japan) as previously described. 28 Briefly, sections were observed and photographed using an Olympus BX50 microscope system (Olympus Corp., Tokyo, Japan). Five randomly selected fields of view (4.3 × 3.2 mm)
were captured at 100× magnification, and the CEA expression area that stained brown was extracted automatically using two distinct macroinstructions composed chiefly of algorithms for color extraction based on red-green-blue (RGB) and hue-luminosity-saturation (HLS) parameters. CEA-positive rate was determined by dividing the area stained with diaminobenzidine (DAB) by the entire area selected, and the average rate of the five fields was calculated.
| RE SULTS
| Cellular imaging and fluorescence intensity
We first attempted to image five CRC cell lines with various expression levels of EGFR using AF488-EGFR-Ab, and determined Pearson's correlation test).
| In vivo molecular imaging of LIM1215 and COLO320DM xenograft tumors in nude mice
Based on the results of cellular imaging, in vivo molecular imaging was carried out using three mice xenografted with a cell line that highly expresses EGFR (LIM1215) and a low-EGFR expression cell Figure 4C ). In contrast, H&E staining in 5-FU-treated tumor tissue showed extensive fibrosis and necrosis ( Figure 4D ).
In order to quantify the viable cells in tumor tissues, we carried out immunohistochemical staining for CEA, which is reportedly a good marker of CRC cells with high sensitivity and specificity. 29, 30 Representative CEA staining patterns in tumors after treatment with vehicle alone or 5-FU are shown in Figure 4E Figure 4F ). The mean CEA-positivity rate in 5-FU-treated tumors was 31.4 ± 11.1%, which was significantly lower than that in the control group treated with vehicle alone (72.6 ± 3.0%, Figure 4G ).
Moreover, there was a significant correlation between the percentage decrease in fluorescence intensity and the CEA-positivity rate in each tumor ( Figure 4H , P < .01 by Pearson's correlation test). These data suggest that fluorescence intensity reflects the viable cell volume of the tumor after treatment with anticancer drugs. Thus, our imaging method is suitable for evaluation of the therapeutic efficacy of anticancer drugs.
| Molecular imaging of colorectal tumors by endoscopy in AOM-treated rats
In vivo molecular imaging of colorectal tumors in AOM-treated rats was carried out using a veterinary endoscope. Figure S4 ).
Observation of the colorectal mucosa removed from the mouse showed a polyp that was visible to the naked eye ( Figure 5E ). The tumor was diagnosed as adenoma based on histological staining with H&E staining ( Figure 5F ). EGFR immunohistochemistry of the lesion showed a clear expression of EGFR in the tumor cells ( Figure 5G ) despite a faint non-specific signal with rabbit IgG as a negative control ( Figure 5H ).
We observed colorectums of 10 rats using white light and fluorescence imaging with AF488-EGFR-Ab. White light observation showed one polyp in each colorectum of six rats, and no polyps in the colorectum of the remaining four rats. Average diameter of the polyps observed was 2.17 ± 0.37 mm. Molecular imaging with AF488-EGFR-Ab detected all these polyps in the same location as that observed with white light, although no additional new polyps were detected (Table 1) . These results suggest that EGFR molecular imaging using our veterinary fluorescent endoscopic system may be able to detect a small polyp with a diameter of approximately 2 mm.
| D ISCUSS I ON
In the present study, we clearly visualized CRC cells using non-inva- Currently, clinical evaluation of the therapeutic effect of anticancer agents on solid cancers is done using RECIST guidelines. 6, 7 RECIST assessment is carried out by measuring the diameter of each tumor before and after treatment using CT images. However, detected colitis-associated cancer in mice with a high target-to-background ratio. 36 However, given the longer survival period of CRC patients as a result of the use of molecular-targeting agents, it is not practical to repeatedly use this radioactive modality in patients. 37, 38 Optical molecular imaging technologies, such as the one used in the present study, are less harmful and easier to use than procedures 
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involving radioactive agents. Here, we showed that our EGFR-targeted imaging reflected viable tumor cells. This was also consistent with our ex vivo data of xenograft tumors in terms of distribution of AF-EGFR-Ab; when frozen sections of tumor were observed at low magnification under fluorescent microscopy, strong fluorescent signals were detected throughout the tumor from mice treated with vehicle alone, whereas reduced levels of fluorescence were detected in tumors from mice treated with 5-FU that gave a dappled distribution of signals ( Figure S6 ). However, the relationship between fluorescent intensity and viable tumor cell volume should be investigated further. In addition, our EGFR-targeted imaging to evaluate the effects of cancer therapy assumes that EGFR expression is not downregulated or upregulated by the chemotherapy itself. To address this point, we investigated relative mRNA levels and EGFR number in CRC cells before and after 5-FU treatment, and confirmed that there are no significant changes before and after 5-FU treatment ( Figure   S7 ). Thus, EGFR-targeted imaging is a potentially useful tool for evaluating therapeutic efficacy.
In the present study, we were able to detect all six small adenomas that were 2-3 mm in diameter. To date, no studies have reported the detection of colorectal adenomas using EGFR-targeted molecular imaging. Thus, EGFR-targeted molecular imaging may lead to the development of a sensitive detection method for adenoma.
However, this study was limited to cell lines and animal experiments and, therefore, further investigation for clinical application will be needed.
For clinical administration with fluorescent probes, two routes can be used to give AF-EGFR-Ab: local administration by direct spraying and i.v. administration. In the present study, we gave AF-EGFR-Ab by enema and obtained a relatively high S/N ratio (10.6 ± 0.7). When AF-EGFR-Ab was given i.v. to mice in preliminary experiments, the tumor was also visualized with the fluorescent signal although the S/N ratio was relatively low (4.0 ± 0.6; Figure S8 ).
Further experiments with more animals are required to compare the two administration routes.
Image brightness of the veterinary endoscope used in this study was low as a result of its thinness ( Figure 5A ), and the brightness of our fluorescence endoscopy system with the blue and yellow fil- Therefore, when fluorescence molecular imaging of EGFR is applied to future human colonoscopy, it will be possible to obtain much brighter and clearer images for detection of colorectal tumors.
In conclusion, the results of our animal experiments suggest that EGFR-targeted molecular imaging may be useful for evaluating chemotherapeutic efficacy, as indicated by viable cell volume, more accurately than tumor size. This EGFR imaging method may also be useful in detecting colorectal adenoma in the colorectum for colonoscopy. This imaging method may lead to advancements in early detection and improved diagnosis of colorectal tumors, as well as therapeutic evaluation of CRC.
ACK N OWLED G M ENTS
The authors are grateful to Dr Masayuki Shono and Dr Kazuki
Horikawa for their expert technical assistance.
D I SCLOS U R E
Authors declare no conflicts of interest for this article.
O RCI D
Yoshihiko Miyamoto https://orcid.org/0000-0002-4876-9156
Tetsuji Takayama https://orcid.org/0000-0002-0175-1573
R E FE R E N C E S
